Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yasuhiro Koh

Showing results (141-150 of 144) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 144 results.
British Journal of Cancer|October 4, 2017
Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) studyEiji Shinozaki, Takayuki Yoshino, Kentaro Yamazaki, et al.
International Journal of Clinical Oncology|March 1, 2023
Regulation of MEK inhibitor selumetinib sensitivity by AKT phosphorylation in the novel BRAF L525R mutantChikako Nakai, Sachiyo Mimaki, Koutatsu Matsushima, et al.
International Journal of Hematology|September 19, 2020
Pembrolizumab plus lenalidomide and dexamethasone in treatment-naive multiple myeloma (KEYNOTE-185): subgroup analysis in Japanese patientsNaoki Takezako, Hiroshi Kosugi, Morio Matsumoto, et al.
European Journal of Cancer (Oxford, England : 1990)|June 12, 2020
Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G)Daisuke Sakai, Hiroya Taniguchi, Naotoshi Sugimoto, et al.
Pageof 15

Showing results (141-150 of 144) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 144 results.
British Journal of Cancer|October 4, 2017
Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) studyEiji Shinozaki, Takayuki Yoshino, Kentaro Yamazaki, et al.
International Journal of Clinical Oncology|March 1, 2023
Regulation of MEK inhibitor selumetinib sensitivity by AKT phosphorylation in the novel BRAF L525R mutantChikako Nakai, Sachiyo Mimaki, Koutatsu Matsushima, et al.
International Journal of Hematology|September 19, 2020
Pembrolizumab plus lenalidomide and dexamethasone in treatment-naive multiple myeloma (KEYNOTE-185): subgroup analysis in Japanese patientsNaoki Takezako, Hiroshi Kosugi, Morio Matsumoto, et al.
European Journal of Cancer (Oxford, England : 1990)|June 12, 2020
Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G)Daisuke Sakai, Hiroya Taniguchi, Naotoshi Sugimoto, et al.
Pageof 15